Regulating obesity-induced osteoarthritis by targeting p53-FOXO3, osteoclast ferroptosis, and mesenchymal stem cell

Chen Zhao1, Keyu Kong1, Pengcheng Liu2

  • 1Department of Orthopedics, Shanghai Key Laboratory of Orthopedics Implant, the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

PubMed

Insights

Obesity accelerates osteoarthritis by damaging cartilage and bone. Enhancing FOXO3 gene expression in joint cells can inhibit this progression, offering new therapeutic targets for obesity-related joint disease.

Area of Science:

  • Biomedical research
  • Molecular biology
  • Orthopedics

Background:

  • Obesity-related osteoarthritis (OA) mechanisms and joint structural changes are poorly understood.
  • Existing knowledge gaps hinder effective therapeutic strategies for obesity-induced OA.

Purpose of the Study:

  • To investigate the molecular mechanisms of obesity-related OA progression in mice.
  • To validate findings in human joint samples.
  • To identify potential therapeutic targets for obesity-related OA.

Main Methods:

  • Obesity progression was studied in mouse models.
  • Human joint samples from post-arthroplasty patients were used for validation.
  • Gene expression analysis, cell apoptosis assays, and osteoclast differentiation studies were performed.
  • Intra-articular lentiviral delivery of FOXO3 was used in mouse models.

Main Results:

  • Obesity is linked to cartilage degeneration and subchondral bone remodeling, associated with aging and DNA damage in joint cells.
  • p53-FOXO3 gene loop regulation in response to DNA damage inhibits chondrocyte apoptosis and osteoclast differentiation.
  • Intra-articular FOXO3 delivery ameliorated OA progression in mice.
  • Subchondral bone marrow osteoclast differentiation is ferroptosis-dependent and driven by senescence-associated secretory phenotype.

Conclusions:

  • The p53-FOXO3 pathway is a key regulator in obesity-related OA.
  • Targeting ferroptosis and senescence-associated secretory phenotype may offer new avenues for OA treatment.
  • FOXO3 delivery shows therapeutic potential for obesity-related osteoarthritis.